| Date | Title | Description |
| 14.10.2025 | Financial boost for publicly traded scale-ups |
ADC Therapeutics SA, a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in ... |
| 06.08.2024 | ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt | ZYNLONTA® – Nettoumsatz von 17,0 Mio. USD im 2. Quartal 2024; kommerzielle Rentabilität in der ersten Hälfte des Jahres 2024 erreicht
Rekrutierung für die LOTIS-7-Studie verläuft planmäßig; Wirksamkeits- und Sicherheitsdaten zu den in Frage... |
| 06.08.2024 | ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update | ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024
LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on a... |
| 06.08.2024 | ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt | ZYNLONTA® – Nettoumsatz von 17,0 Mio. USD im 2. Quartal 2024; kommerzielle Rentabilität in der ersten Hälfte des Jahres 2024 erreicht
Rekrutierung für die LOTIS-7-Studie verläuft planmäßig; Wirksamkeits- und Sicherheitsdaten zu den in Frage... |
| 05.06.2024 | Nucleus RadioPharma Secures Investment from AstraZeneca | What You Should Know:
– Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
– The strategic ... |
| 06.05.2024 | ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants | LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to ... |
| 06.05.2024 | ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants | - |
| 16.04.2024 | ADC Therapeutics Accelerates R&D with Genedata Biologics | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Enterprise software solution streamlines development of breakthrough antibody dr... |
| 13.03.2024 | ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates | - |
| 06.03.2024 | ADC Therapeutics gibt die Annahme von Abstracts zur Präsentation auf der Jahrestagung der American Association for Cancer Research (AACR) bekannt | - |
| 06.03.2024 | ADC Therapeutics veranstaltet am 13. März 2024 eine Telefonkonferenz zu den Finanzergebnissen für das vierte Quartal und das Jahresende 2023 | - |
| 06.03.2024 | ADC Therapeutics nimmt am Guggenheim 5th Annual Healthy Altitudes Summit teil | - |
| 06.03.2024 | ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit | - |
| 05.03.2024 | ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting | - |
| 20.11.2023 | Sobi to present new data at ASH 2023 Annual Meeting | Sobi to present new data at ASH 2023 Annual Meeting
Mon, Nov 20, 2023 08:00 CET Report this content
Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of ... |
| 02.06.2023 | Sobi to present new data at the 2023 EHA congress | Sobi to present new data at the 2023 EHA congress
Fri, Jun 02, 2023 09:00 CET Report this content
Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023, high... |
| 28.12.2022 | ADC Therapeutics gains EU clearance for Zynlonta | |
| 21.12.2022 | Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma | Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Wed, Dec 21, 2022 08:00 CET Report this content
Sobi® and ADC Therapeutics SA today announced that the European ... |
| 16.09.2022 | Loncastuximab tesirine receives positive CHMP opinion for the treatment of relapsed or refractory diffuse large B-cell lymphoma | Loncastuximab tesirine receives positive CHMP opinion for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Fri, Sep 16, 2022 13:15 CET Report this content
Loncastuximab tesirine receives positive CHMP opinion for the tr... |
| 09.05.2022 | Seagen CEO Clay Siegall was placed on leave after an April 23 arrest for domestic violence gross misdemeanor | Around a year ago, Ameet Mallik left his post at Novartis, where he had spent the last 16 years, to champion a drug for metastatic pancreatic cancer as CEO at Rafael Holdings. However, just half a year in, the company took a nosedive as tha... |
| 19.01.2022 | ADC Therapeutics secures $30 million in new partnership deal | |
| 19.01.2022 | ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA (loncastuximab tesirine-lpyl) in Japan | LAUSANNE, Switzerland - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematolo... |
| 04.11.2021 | ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting - Form 6-K | ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination for t... |
| 27.08.2021 | ADC Therapeutics signs financial agreement for up to $325 Million | |
| 26.08.2021 | ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal | ADC Therapeutics will receive $225 million in cash and an additional $100 million in near-term milestones as part of a royalty sale with HealthCare Royalty for its lead antibody-drug conjugate Zynlonta and investiga... |
| 09.06.2021 | ADC THERAPEUTICS SA
ADC Therapeutics : Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma (Form 6-K) | ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
Oral presentation of preliminary results from ongoing pivotal Phase 2 trial of camidanlumab tesirine in r/r Hodgkin lymphoma
LOTIS tr... |
| 06.05.2021 | ADC Therapeutics : Reports First Quarter 2021 Financial Results and Provides Business Updates | ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today reported financial results for the first... |
| 27.04.2021 | ADC Therapeutics obtains its first FDA approval for its Lymphoma cancer treatment | |
| 27.04.2021 | ADC Therapeutics obtains its first FDA approval for its Lymphoma cancer treatment | Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in the United States, is a rapidly progressing, aggressive disease that is heterogeneous with multiple subtypes.2 More than 40% of first-line DLBCL treatmen... |
| 14.12.2020 | ADC Therapeutics launches Joint Venture for the Chinese market | |
| 14.12.2020 | ADC Therapeutics launches Joint Venture for the Chinese market | Under the terms of the agreement, ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT BioPharma. Overland Pharmaceuticals ha... |
| 20.11.2020 | ADC Therapeutics Announces FDA’s Acceptance of its Biologics License Application | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company ADC Therapeutics SA (“ADC” or the “Company”), a late clinical st... |
| 05.07.2020 | ADC Therapeutics Completes $267M IPO | ADC Therapeutics (NYSE:ADCT), a Swiss and US late clinical-stage oncology-focused biotechnology company, raised $267.6m through its IPO.
ADC, which is a portfolio company of New Ventures Funds, a venture fund targeting investments in compan... |
| 30.06.2020 | ADC THERAPEUTICS SA
ADC Therapeutics : New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO | VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:AD... |
| 22.05.2020 | Successful IPO of ADC Therapeutics | ADC Therapeutics closed its initial public offering of 14,082,475 shares of its common shares at a price of $19.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,836,844 additional common sh... |
| 22.05.2020 | Successful IPO of ADC Therapeutics | |
| 20.05.2020 | 4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company ADC Therapeutics SA, a late clinical stage oncology-focused biot... |
| 15.05.2020 | ADC Therapeutics aims to raise $230 million in IPO | |
| 15.05.2020 | ADC Therapeutics aims to raise $230 million in IPO | ADC Therapeutics SA headquarted at Biopôle in Epalinges close to Lausanne is a late clinical-stage oncology-focused biotechnology company developing antibody drug conjugates for patients suffering from hematological malignancies and solid t... |
| 11.05.2020 | Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms | → Fritz Gerber, the 92-year-old ex-Roche CEO who steered the company to a majority stake in Genentech, has died. Gerber was CEO from 1978 to 1998, and chairman for a few years after that. The company credits him with taking a ... |
| 27.04.2020 | Second attempt: ADC Therapeutics starts IPO process | |
| 27.04.2020 | Second attempt: ADC Therapeutics starts IPO process | ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological mal... |
| 13.09.2019 | ADC Therapeutics recognized with Excellence Award at Convergence in Oncology Summit | |
| 10.09.2019 | ADC Therapeutics to go public | |
| 06.08.2019 | Two Swiss scale-ups team up to fight cancer | |
| 10.07.2019 | ADC Therapeutics finalises a $303M series E round | |
| 12.06.2019 | ADC Therapeutics raises additional $76 million | |
| 12.06.2019 | ADC Therapeutics beefs up monster $200M round with fresh $76M haul | Days after Roche secured accelerated approval for its antibody-drug conjugate, Lausanne, Switzerland-based ADC Therapeutics has clinched another $76 million to its already hefty $200 million round of financing unveil... |
| 07.08.2018 | ADC Therapeutics doses first patient in Phase II clinical trial | |
| 24.10.2017 | Term Sheet — Tuesday, October 24 | THREE THINGS
Good morning, Term Sheet readers.
Paid Content A.I. is the answer to protecting your enterprise in the cloud From ExtraHop
UBER DRAMA: Saudi Arabia’s state-owned Public Investment Fund is expected to discuss its strategy at the... |
| 23.10.2017 | ADC Therapeutics Announces Closing of $200 Million Private Financing | |
| 23.10.2017 | ADC Therapeutics Closes $200M Financing | ADC Therapeutics (ADCT), a Lausanne, Switzerland-based oncology drug discovery and development company, raised $200m in funding.
The round was led by both existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Of... |
| 27.10.2016 | ADC Therapeutics Announces Closing of $105 Million Private Financing | |
| 02.09.2015 | Daily funding roundup - September 2, 2015 | Tanium landed $120M; NewsCred bagged $42M; Universal Avenue secured $5M
ConnectedYard, an innovator in smart technology and the Internet of Things (IoT), today announced that it has closed a $2.2-million seed round of funding led by Playgro... |
| 02.09.2015 | ADC Therapeutics Secures $80m Financing | |
| 02.09.2015 | ADC Therapeutics Raises $80M in Equity Funding | ADC Therapeutics, a Lausanne, Switzerland-based oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, raised $80m in equity funding.
New i... |
| 15.10.2013 | MedImmune and Auven invest USD 40 million in ADC Therapeutics | |
| - | ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates | LAUSANNE, Switzerland--(BUSINESS WIRE)--Mar 18, 2021--
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conj... |
| - | ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference | LAUSANNE, Switzerland--(BUSINESS WIRE)--Feb 25, 2021--
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody dru... |
| - | ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021 | LAUSANNE, Switzerland--(BUSINESS WIRE)--Mar 11, 2021--
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody dr... |
